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Summary Background: Bacterial pneumonia involves influx of activated phagocytes
into distal airways. These cells release oxidants including H2O2, that may be exhaled
or induce peroxidative damage to lung tissues with formation of thiobarbituric
reactive substances (TBARs).
Study objectives: To determine whether concentrations of H2O2 and TBARs in
exhaled breath condensate (EBC) is elevated and correlate with systemic response to
pneumonia during 10 days of hospital treatment.
Design: The concentration of H2O2 and TBARs was measured in EBC of 43 inpatients
with community acquired pneumonia (CAP) and 20 healthy never smoked subjects
over 10 days and were accompanied by monitoring of WBC count, serum
concentration of C-reactive protein (CRP) and peroxyl radical-trapping capacity.
Results: Patients with CAP exhaled 4.6-, 3.7-, 3.9-, 3.3-times more H2O2 than
healthy controls at 1st, 3rd, 5th and 10th day of treatment (Po0:05), respectively.
EBC concentrations of TBARs were elevated at 1st and 3rd day. H2O2 and TBARs levels
decreased along with treatment course. Correlation (Po0:05) was found between
H2O2 levels and CRP and WBC count (r ¼ 0:31) at 1st day and between TBARs and CRP
at 5th (r ¼ 0:34) and 10th day (r ¼ 0:46). The mean H2O2 exhalation estimated over
ten days of treatment correlated with pneumonic chest X-ray score (r ¼ 0:42), CRP
levels (r ¼ 0:46) and WBC count (r ¼ 0:33) at admission (Po0:05).
Conclusions: Pneumonia is accompanied by oxidative stress in airways that
moderately correlates with intensity of systemic inflammatory response. Determina-
tion of H2O2 in EBC may be helpful for non-invasive monitoring of oxidants
production during lower respiratory tract infection.
& 2004 Elsevier Ltd. All rights reserved.
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Introduction
Bacterial pneumonia is characterized by rapid and
large influx of activated phagocytes into distal
airways. These cells release a lot of reactive
oxygen species (ROS) including H2O2 that plays
the central role in formation of highly reactive and
cytotoxic hydroxyl radicals and hypochlorous acid.1
Both, these compounds contribute to non-specific
host defence against invading microorganisms.
However, enhanced ROS production may induce
peroxidative damage to lipids and other biomole-
cules leading to accumulation of toxic products
that are commonly detected by their reaction with
thiobarbituric acid.2 Malondialdehyde is one of the
most important of so-called thiobarbituric reactive
substances (TBARs). Since, H2O2 and malondialde-
hyde are relatively stable and volatile they may be
measured in exhaled breath condensate (EBC) of
healthy subjects3 and those with chronic inflam-
matory lung disorders.4–8 Increased levels of H2O2
were also reported in EBC obtained from mechani-
cally ventilated patients due to acute respiratory
insufficiency caused by severe pneumonia.9,10
However, these studies were mainly limited to
H2O2 determinations in EBC collected at the first
day after admission. No trials devoted to time-
course of H2O2 and TBARs exhalation in subjects
with pneumonia along with improvement of pa-
tients’ clinical status have been performed so far.
Therefore, we decided to monitor the exhalation of
H2O2 and TBARs in subjects with community
acquired pneumonia (CAP) during successful 10
day treatment versus age- and sex-matched
healthy controls. Furthermore the associations
between exhaled compounds and pneumonic chest
X-ray score, serum peroxyl radical-trapping capa-
city (sPRTC) and selected markers of systemic
inflammatory response were also investigated.
Materials and methods
Patients and treatment
The study population included 43 patients (12
women, 31 men) with CAP admitted to Institute
of Internal Medicine in the 1st Academic Teaching
Hospital of Medical University of Lodz from May
2000 to May 2001 (Table 1). Each enrolled patient
had to fulfil the following inclusion criteria: (1)
ageX18 years; (2) presence of a new infiltrate (s),
consolidation or pleural effusion consistent with
pneumonia on a chest radiograph at the day of
admission; (3) at least two of the following signs
and symptoms: new or increased cough, purulent
sputum, rales at auscultation and evidence of
pulmonary consolidation, tachypnoea or hypoxe-
mia, pleuritic chest pain; (4) at least one of the
following signs and symptoms: fever (tympanic
temperature of 438.51C) or a history of fever for
the current episode of CAP, total peripheral white
blood cells (WBC) count of 410 000 cells/mm3 or
415% immature neutrophils (bands) regardless of
total WBC count or leucopenia with total WBC
count o4500 cells/mm3; (5) negative urine preg-
nancy test (for women of child-bearing potential)
at the day of admission. The exclusion criteria
were: (1) female patient who is pregnant or
lactating (breast feeding); (2) aspiration pneumo-
nia or hospital acquired pneumonia; (3) cystic
fibrosis, active tuberculosis, bronchiectases, active
malignancies, signs of disseminated infection, renal
impairment (creatynine clearance ofo30ml/min),
liver impairment (alanine-amino transferaseFALT,
aspartate-amino transferaseFASTor alkaline phos-
phatase levels greater than 3 times the upper limit
of normal) or presence of any serious unstable
underlying disease; (4) active alcohol or drug
abuse; (5) not refraining from cigarette smoking
within 12 h before EBC collection. Angiotensin
converting enzyme (ACE) inhibitors-controlled hy-
pertension and chronic bronchitis related to cigar-
ette smoking were the only allowed concomitant
diseases. The empiric antibacterial therapy started
at the day of admission and drugs were adminis-
tered daily in the standard dosages for 7 days.
Nineteen patients were treated with cephalospor-
ins, 9 with quinolones, 9 with combination of
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Table 1 Baseline characteristic of study subjects.
CAP patients Healthy controls
Number 43 20
Sex F/M 12/31 6/14
Mean age, yrs 67712 50710
Smokers 18 0
Non-smokers 25 20
BMI 23.173.7 25.073.2
FVC% 58.176.8* 103.6719.3
FEV1% 55.3718.6* 100.6720.4
FEV1/FVC 92.7719.4 101.677.5
Pneumonic score 3.871.3 0#
CAP–community acquired pneumonia, FVCFforced vital
capacity, FEV1Fforced expiratory volume in the first
second, BMIFbody mass index. FEV1 and FVC are
expressed as percent of predicted value [35]. #FChest
X-ray was not done and pneumonic chest X-ray score was
assumed to be 0 on the basis of patient medical history
and result of physical examination. *FPo0:05 vs.
control.
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cephalosporin plus aminoglycoside, 2 with combi-
nation of cephalosporin plus quinolone and 4 with
amoxicillin/clavulanate, respectively. Concomitant
medication included, N-acetylcysteine (NAC) effer-
vescent tablets 600mg/day (n ¼ 41), theophylline
300mg twice a day (n ¼ 39) and ACE inhibitors,
captopril 12.5mg or 25mg two or three times a day,
or enalapril 10–20mg once a day (n ¼ 12). Treat-
ment with ACE inhibitors was a continuation of out-
patient medication started at least one month
before patient admission. The control healthy
subjects included 20 volunteers (Table 1) who
had never smoked and had not suffered from
any infectious disease for at least 3 months
prior to the study. They were free from any
medication and had no history of respiratory or
atopic disease. All patients involved in the study
gave informed consent and the study protocol
was approved by Ethics Committee of Medical
University of Lodz.
Study protocol
At the day of admission chest X-ray, serum
chemistry, haematology, urinalysis has been per-
formed and blood and sputum specimens for
culture were collected from patients with CAP.
The chest X-ray was analyzed by pulmonologist and
radiologist and the intensity of pneumonic changes
was recorded on a scale from 0 (no symptoms) to 10
points. The number of pulmonary fields (from 0 to 6
points) involved by inflammatory infiltrate (con-
solidation) was the first evaluated element. One or
two points were added if the opacity was inhomo-
geneous and mostly hazy or dense and coalesce to
form confluent areas of pulmonary shadowing,
respectively. Additional one or 2 points were
calculated when pleural effusion or bilateral effu-
sion was present. Thus, maximal score 10 could be
calculated for patient who had bilateral pleural
effusion and dense confluent inflammatory shadows
present in all 6 pulmonary fields. EBC specimens
were collected between 8 and 10 a.m.3,11 at 1st,
3rd, 5th and 10th (discharge) day of hospitaliza-
tion. Patients who were current smokers were
asked to refrain from cigarette smoking for 12 h
preceding EBC collection. If a patient failed to
refrain from smoking collection was performed the
day later. This occurred in 4 patients; 2 at 3rd day
and 2 at 5th day, respectively. EBC from healthy
subjects was collected at the same time-points. To
avoid any bias each healthy subject was randomly
paired with one patient with CAP and the EBC
collections were performed at the same days. The
spirometry was performed with Flowscreen (Erich
Jaeger GmbH Co., Germany) at 1st and 10th day
just after EBC collection under conditions as
previously described.11 The following parameters
were also measured: serum concentration of
C-reactive protein (CRP) with Beckman Array 360
at 1st, 5th, 10th day of treatment; sPRTC at the
same time-points as EBC collection, and WBC count
at 1st and 10th day, respectively.
Collection of exhaled breath condensate
The collecting device consisted of a plastic mouth-
piece (Art.-No. 892103, Jaeger Toennies, Hoch-
berg, Germany) and saliva trap connected to a glass
Liebig tube-cooler (cooling and collecting tube
55 cm length, internal diameter 10mm, the ex-
ternal jacket diameter 36mm) (Labmed, Lodz,
Poland cat no 6010). The tube was cooled with
ethanol pumped in the closed circuit and its
temperature was kept at 91C with Multi Temp III
(Pharmacia Biotech). This temperature was the
lowest one that allowed to collect liquid EBC in the
sterile plastic tube covered with ice (Sarstedt,
Numbrecht, volume 13ml, internal diameter
14mm) mounted at the base of Liebig tube-cooler.
Further decrease in ethanol temperature caused
congealment of EBC inside the cooling tube and
stopped its collection.11 Patients were asked to
breathe out through a mouthpiece and to breathe
in with the mouthpiece removed, for 20min. The
respiratory rate (tidal breathing) ranged from 17 to
27 breaths/min for patients with pneumonia and
from 16 to 19 breaths/min for healthy controls.
This had no significant influence on measured
variables.3,9 Each subject wore a noseclip and
rinsed their mouth with distilled water just before
and at 7 and 14min of collection.3,5 EBC specimens
were tested for salivary contamination by determi-
nation of amylase levels using Vitros 250 chemistry
system (Johnson & Johnson, Ortho Clinical Diag-
nostics, USA). In all tested samples, no amylase was
detected. All aliquots of EBC were stored in
Sarstedt tubes on ice (but not frozen) until H2O2
and TBARs measurement. After each EBC collection
the plastic parts of collecting device were washed
with detergent solution (Merida, Wroclaw, Poland)
and then disinfected with Sekusepts solution with
addition of Sekusepts activator (Henkel-Ecolab
GmbH, Dusseldorf, Germany) according to manu-
facturer’s instruction. The tube-cooler was washed
with 30% ethanol solution and then rinsed 3-times
with sterile deionized water (resistance
418MO cm, HPLC Water Purification System USF
ELGA, England).
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Measurement of H2O2 and TBARs in exhaled
breath condensate
The concentration of H2O2 was measured within
30min after EBC collection according to the method
of Ruch et al.12 with some modifications.3 The lower
limit of H2O2 detection was 0.083mM.
5 The intra-
assay variability did not exceed 2% for standard H2O2
solutions ranging from 0.1 to 0.5mM. The content of
TBARs in EBC was determined as previously de-
scribed.3,13 Tetramethoxypropane (0.01–50mM) was
used as an external standard and the method
sensitivity was 0.05mM.5 The intra-assay variability
did not exceed 3% for 0.1 and 0.5mM tetramethox-
ypropane solution. The intra-assay variability of
measured H2O2 and TBARs levels was 9.7% and
14.9% as determined with 10 subjects (6 patients
with CAP and 4 healthy controls) asked to attend 2
EBC collection sessions in 30min intervals.
Measurement of serum peroxyl radical-
trapping capacity
In this assay antioxidants present in serum sample
inhibit oxidation of 2,20-azinobis(3-ethylbenzothia-
zoline-6-sulfonic acid) by peroxyl radicals gener-
ated from thermal decomposition of 2,20-azobis
(2-amidopropane) hydrochloride.14,15 Briefly, 3ml
of pre-wormed to 371C 0.1M sodium phosphate
buffer (pH 7.0) was mixed with 90 ml of 5mM 2,20-
azinobis(3-ethylbenzothiazoline-6-sulfonic acid)
solution and different volumes of serum. There-
after 300 ml of 200mM 2,20-azobis (2-amidopro-
pane) hydrochloride was added and the reaction
was carried at 371C. Control samples received
phosphate buffer instead of serum and the absor-
bance was recorded continuously at 414 nm in
double beam spectrophotometer (CARY 1, Varian).
The induction time of the reaction defined as the
time from 2,20-azobis (2-amidopropane) hydro-
chloride addition to the onset of the absorbance
rise was proportional to the amount of antioxidants
present in the sample and was used as the measure
of sPRTC. Results were expressed as the serum
volume that increased 2-fold the induction time of
reaction.
Statistical analysis
Data are expressed as mean7SD. Part of EBC
specimens, especially those obtained from healthy
controls revealed no detectable TBARs. In this case
the TBARs concentration was assumed 0.025mM
(half of the detection limit). The time-courses of
variables were analyzed using Student t and
Wilcoxon matched pairs tests according to sample
distribution. The differences between groups were
computed with Mann-Whitney U test or Friedman
ANOVA test. Correlation coefficients were calcu-
lated by the Pearson test or Spearman test. In all
cases a P-value ofo0.05 was considered significant.
Results
In 25 patients the etiologic agent was found on the
basis of sputum and blood culture. The most
common bacteria were Streptococcus pneumoniae
(n ¼ 14) and Haemophilus influenzae (n ¼ 7).
Serum screening for presence of antibodies against
Chlamydia pneumoniae, Chlamydia trachomatis,
Chlamydia psittaci, Mycoplasma pneumoniae and
Legionella pneumophilia revealed no current in-
fection with these pathogens in any case. In 18
remaining patients the pathogenic bacteria was not
determined. The empiric antibiotic treatment was
successful and all enrolled patients with CAP
finished the study. However, 10 patients were
discharged after 7–8 days of treatment due to
rapid recovery. Therefore, in these patients we
were not able to collect EBC and blood specimens
at the 10th day of treatment, nevertheless, they
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Table 2 Changes of selected parameters in patients with community acquired pneumonia during treatment.
Parameter Day of treatment
1st 3rd 5th 10th
WBC 103/ml 10.275.7 ND ND 8.475.0*
CRP mg/dl 8.774.1 ND 3.572.7* 2.471.8*
SPRTC ml 15.275.7 16.274.9 15.575.0 13.874.8* *
FVC% 58.2717.2 ND ND 74.2721.6*
FEV1% 55.6718.9 ND ND 67.8723.7*
FEV1/FVC 92.2719.6 ND ND 93.5716.6
WBCFwhite blood cell count, CRPFC-reactive protein, sPRTCFserum peroxyl radical-trapping capacity, NDFnot
determined. *Fvs. value at 1st day; Po0:05; * *Fvs. value at 3rd day; Po0:05:
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were included in statistical analysis. The significant
improvement in forced vital capacity (FVC) and
forced expiratory volume in the first second (FEV1)
was observed in patients with CAP. This was
accompanied by gradual normalization of serum
CRP levels and WBC count. sPRTC was stable over
the first 5 days of treatment and then the rise in
this parameter was observed (Table 2).
Time course of H2O2 and TBARs exhalation in
CAP patients and healthy controls
Patients with CAP exhibited elevated H2O2 levels in
EBC (Fig. 1). At 1st, 3rd, 5th and 10th day of
treatment H2O2 exhalation was 4.671.7-, 3.77
1.9-, 3.971.5- and 3.371.4-fold higher (Po0:05)
than in healthy controls. The highest mean EBC
H2O2 levels were at 1st and 3rd day of treatment.
Then the H2O2 exhalation gradually decreased
revealing the significant differences between va-
lues found at 3rd and 5th day and at 3rd and 10th
day (Po0:05), respectively. The mean H2O2 exhala-
tion estimated over the whole treatment period
(calculated as a mean of measurements performed
at day 1st, 3rd, 5th and 10th) was also higher in CAP
patients than in healthy subjects (Table 3). In
accordance with our previous studies3 healthy
subjects exhaled only trace amounts of TBARs. At
1st and 3rd day of TBARs exhalation monitoring no
EBC specimen from healthy subjects revealed
positive result. Only 2 and 3 of 20 healthy subjects
had detectable amounts of TBARs at 5th and 10th
day of study. The ratio of positive TBARs readings in
CAP patients ranged between 0.21 and 0.37 over
the treatment period. Thus, TBARs exhalation was
higher in patients with CAP than in healthy
controls, however, only at 1st and 3rd day of
treatment the differences were significant
(Table 4). Mean TBARs exhalation estimated over
the treatment period was higher in CAP patients
than in healthy controls (Table 3).
Correlations between exhaled compounds
and clinical parameters
Exhaled H2O2 moderately correlated with WBC
count (r ¼ 0:31; Po0:05) and serum CRP (r ¼ 0:31;
Po0:05) at the day of admission. The weak, but
significant (Po0:05) positive association between
pneumonic chest X-ray score at the day of admis-
sion and EBC H2O2 levels at 3rd (r ¼ 0:14) and 5th
day (r ¼ 0:18) of treatment was observed. TBARs
levels correlated only with serum CRP concentra-
tions at 5th (r ¼ 0:34; Po0:05) and 10th (r ¼ 0:46;
Po0:05) day of treatment. No other significant
associations were noted between exhaled variables
and clinical parameters (data not shown). A
moderate negative correlation between exhaled
H2O2 and TBARs was noted in CAP group (r ¼ 0:42;
Po0:05) at the 10th day of treatment. On the other
hand mean H2O2 exhalation estimated over the
treatment period correlated significantly with
pneumonic chest X-ray score (Fig. 2), CRP levels
(Fig. 3) and WBC count (r ¼ 0:33; Po0:05) at the
day of admission. In the case of mean TBARs level
estimated over the treatment period the only
association was with sPRTC at 5th day (r ¼ 0:42;
Po0:03). No associations between exhaled vari-
ables and treatment with various antibiotics,
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Figure 1 H2O2 exhalation by patients with CAP over ten
day treatment period. Results are expressed as mean
H2O2 concentration in expired breath condensate (EBC).
(K) patients with CAP (n ¼ 43); (J) healthy controls
(n ¼ 20). Due to rapid recovery 10 patients with CAP
were discharged before EBC collection at the last time-
point. Thus, the mean H2O2 exhalation at 10th day of
treatment was calculated from 33 individual results. ( * )
significantly different vs. corresponding value found for
healthy subjectsFPo0:05; (#) significantly different vs.
H2O2 levels noted at the 3rd day of treatmentFPo0:05:
Table 3 Comparison of mean H2O2 and TBARs
exhalation estimated over the whole treatment
period in healthy subjects and patients with
community acquired pneumonia (CAP).
Variable (mM) CAP patients Healthy controls
H2O2 0.5970.24* 0.1670.06
TBARs 0.0770.03* 0.0370.01
The mean H2O2 and TBARs exhalation estimated over the
treatment period was calculated as a mean of four
consecutive measurements performed at day 1st, 3rd, 5th
and 10th. *Fvs. healthy controls, Po0:05:
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ACE inhibitors, pathogen species and cigarette
smoking was observed over the whole study period
(data not shown).
Discussion
We found that adult patients with CAP exhale
increased amounts of H2O2 and TBARs over
10 day period of successful treatment. TBARs
concentrations were elevated up to 3rd day
of monitoring while the EBC H2O2 levels decreased
along with treatment but at the day of discharge
they were still higher than in healthy controls.
This may result from persistence of alveolar
inflammatory infiltrate with H2O2 producing
cells that may be visible on chest-X-ray for few
weeks after the disease onset.16 Elevated H2O2
and TBARs exhalation proves the occurrence
of oxidative stress in the respiratory tract related
to lower airways infection and is compatible with
previous studies showing increased levels of circu-
lating markers of peroxidative damage to biomole-
cules in subjects with bacterial pneumonia.16,17
We suppose that activated polymorphonuclear
leukocytes, monocytes and macrophages present in
alveolar inflammatory infiltrate are the main
source of exhaled H2O2. In patients with bronch-
iectases EBC H2O2 levels positively correlated with
percentage of neutrophils in induced sputum.18
Exhaled H2O2 correlated also with plasma lysozyme
(a measure of in vivo neutrophil turnover) in
patients with adult respiratory distress syndrome.19
In addition intrapulmonary oxygen consumption
rose in mechanically ventilated patients with
pneumonia what may be a consequence of in-
creased oxidative metabolism of polymorphonuc-
lear leukocytes and macrophages constituting
alveolar infiltrate.20 On the other hand, macro-
phages and polymorphonuclear leukocytes contain
catalase and peroxidases21,22 that decompose
H2O2. Thus larger phagocyte influx and degranula-
tion may increase catalase activity in the airways.22
Type II pneumocytes also contain catalase and are
able to release H2O2 into the alveolar spaces.
23
These may be responsible for week correlations
between exhaled compounds and pneumonic chest
X-ray score. It should be noted that pneumonic
chest X-ray score as a simple and non-expensive
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Figure 2 Positive correlation between pneumonic chest
X-ray score at the day of admission and mean H2O2
exhalation estimated over the whole 10 day treatment in
patients with community acquired pneumonia.
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Figure 3 Positive correlation between serum CRP
concentrations at the day of admission (1st day) and
mean H2O2 exhalation estimated over the whole 10 day
treatment in patients with community acquired pneumonia.
Table 4 Concentration of TBARs (mM) in exhaled breath condensate of patients with community acquired
pneumonia (CAP) and healthy controls over ten day treatment/monitoring period.
Group Day of treatment/monitoring
1st 3rd 5th 10th
CAP patients n ¼ 43 0.0770.04* 0.0870.04* 0.0670.03 0.0570.02
Healthy controls n ¼ 20 0.02570.00 0.02570.00 0.0470.01 0.0570.01
*FSignificantly different vs. corresponding value found for healthy subjectsFPo0:05:
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measure of size and severity of inflammatory
alveolar infiltrate has some limitations that may
affect analyzed correlations. This parameter did
not include spatiality of infiltrate and changes in
airflow in the close neighborhood of inflamed areas
that is necessary for H2O2 movement into EBC.
Antibiotic treatment by killing of invading micro-
organisms exerts strong anti-inflammatory activ-
ity24 and seems to be responsible for decline in
H2O2 and TBARs exhalation. Theophylline can
inhibit H2O2 release from human alveolar macro-
phages25 and polymorphonuclear leukocytes26 and
may contribute to decrease in EBC H2O2 levels too.
Almost all patients with CAP received N-acetylcys-
teine that posses direct antioxidant properties and
serves as a precursor for reduced glutathione
synthesis.27 In a placebo controlled study N-
acetylcysteine 600mg a day significantly decreased
H2O2 exhalation after 6 month administration
whilst TBARs levels were not changed in subjects
with stable chronic obstructive pulmonary dis-
ease.11 Therefore, treatment with N-acetylcys-
teine seems to be not responsible for decrease in
H2O2 and TBARs exhalation in CAP patients. How-
ever, N-acetylcysteine may contribute to the rise in
sPRTC observed at the end of study. H2O2 and TBARs
correlated positively with WBC count and serum
CRP levels what indicates associations between
systemic inflammatory response and ROS formation
in the lower airways during pneumonia. Human
plasma contains detectable amounts of H2O2.
28 It
can not be excluded that H2O2 released from
circulatory phagocytes may diffuse from blood
stream through pulmonary endothelium into the
lower airways and undergo exhalation.
This may partially explain the association be-
tween EBC H2O2 levels and WBC count. However,
plasma, erythrocytes and pulmonary endothelium
contain variety of antioxidants28,29 making unlikely
the H2O2 flow from blood into lungs in patients with
CAP. We did not find any significant positive
association between H2O2 and TBARs concentra-
tions in EBC collected at all time-points. This is
consistent with our previous study showing no
correlation between elevated EBC levels of H2O2
and TBARs in subjects with stable chronic obstruc-
tive pulmonary disease over one year observa-
tion.5,11 Exhaled H2O2 represents a pool which is
not involved in free radical reactions leading to
TBARs formation. Moreover, TBARs are also gener-
ated in enzymatic (independent of ROS) processes
of prostaglandin H2 conversion into thromboxane A2
that are usually enhanced at site of inflamma-
tion.2,30 There is evidence that expression and
activity of antioxidant enzymes may secondarily
rise in response to inflammatory processes.30,31
H2O2 and other ROS activate nuclear factor NF-kB
32
that via cytokines (e.g. IL-1, TNF-a) may induce
synthesis of antioxidant enzymes including super-
oxide dismutase, catalase and glutathione perox-
idase.33,34 The release of catalase from ROS-
damaged cells can also increase antioxidant screen
of airways secretion.22 These may break peroxida-
tive damage to lung tissue and be responsible for
negative association between exhaled TBARs and
H2O2 and sPRTC that was noted at the end of
treatment.
In summary, patients with CAP had elevated EBC
H2O2 and TBARs levels that decreased along with
disease resolution. These prove occurrence of
pulmonary oxidative stress during distal airways
bacterial infection. However, weak or moderate
correlations of exhaled variables with common
markers of systemic inflammatory response and
pneumonic chest X-ray score suggest limited pre-
dictive value of EBC H2O2 and TBARs monitoring in
respect of size and severity of pneumonic infiltrate.
On the other hand, high H2O2 exhalation at 1st
and 3rd day of treatment suggests usefulness of
EBC H2O2 monitoring as an index of ongoing
lower respiratory tract infection. This requires
further studies with inpatients at high risk of
pneumonia (e.g. patients hospitalised in intensive
care unit).
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